Pfizer Corporation

Suobao Rong

Patrick Robert Verhoest

Amy Beth Dounay

Laura Ann McAllister

Vinod Dipak Parikh

Matthew Merrill Hayward

Jamison Bryce Tuttle

Michelle Marie Claffey

Xinmin Gan

Laura Ann Mcallister

Compounds of Formula I: wherein X, Y, Z, R, R, R, Rare as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

KAT II inhibitors

Compounds of Formula X: wherein A, X, Y, Z, R, R, and Rare as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

Bicyclic and tricyclic compounds as KAT II inhibitors

Growing community of inventors

Groton, CT, United States of America

Suobao Rong